Peripheral blood leucocytes ornithine decarboxylase activity in chronic myeloid leukemia patients: prognostic and therapeutic implications.

Tripathi AK, Chaturvedi R, Ahmad R, Asim M, Sawlani KK, Singh RL, Tekwani BL
Leuk Res. 2002 26 (4): 349-54

PMID: 11839377 · DOI:10.1016/s0145-2126(01)00142-4

Leukocytes ornithine decarboxylase (ODC) activity was measured in normal individuals and in patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP) as well as in accelerated phase (CML-AP), with an aim to examine the role of ODC activity in prognostic evaluation of CML patients. Our results showed that ODC activity was significantly higher in CML-CP (41.02+/-25.57nmol/h per 10(7) cells, P<0.005) and CML-AP (67.71+/-44.42nmol/h per 10(7) cells, P<0.001) patients than in normal subjects (3.12+/-1.34nmol/h per 10(7) cells). Furthermore, patients with CML-AP showed higher ODC activity than CML-CP patients (P<0.005). Patients with CML-CP who converted to accelerated phase within 24 months had higher ODC activity (84.58+/-12.81nmol/h per 10(7) cells) than patients who did not convert to accelerated phase (31.13+/-18.24nmol/h per 10(7) cells). The high value of ODC activity was also associated with less clinico-hematological response. We suggest that ODC activity reflects the neoplastic proliferative activity in CML patients and may serve as an additional prognostic marker.

MeSH Terms (14)

Adolescent Adult Aged Biomarkers, Tumor Female Humans Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukocytes Male Middle Aged Ornithine Decarboxylase Predictive Value of Tests Prognosis Up-Regulation

Connections (1)

This publication is referenced by other Labnodes entities: